HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.